+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • PDF Icon

    Report

  • 181 Pages
  • July 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309857
Description Jump to:
The global market for Ulcerative Colitis Therapeutics is estimated at US$7 Billion in 2023 and is projected to reach US$9.5 Billion by 2030, growing at a CAGR of 4.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Oral Administration segment, which is expected to reach US$5.1 Billion by 2030 with a CAGR of 3.9%. The Injectables Administration segment is also set to grow at 5% CAGR over the next 7 years.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $2.1 Billion in 2023, and China, forecasted to grow at an impressive 4.2% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Ulcerative Colitis Therapeutics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Ulcerative Colitis Therapeutics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Ulcerative Colitis Therapeutics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Abbott Laboratories, Inc., AbbVie, Inc., Amgen, Inc., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 16 Featured):

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Amgen, Inc.
  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Avaxia Biologics, Inc.
  • BioLineRx Ltd.
  • Celgene Corporation
  • Cosmo Pharmaceuticals NV
  • EA Pharma Co., Ltd.
  • Eisai Co., Ltd.
  • Ferring Pharmaceuticals
  • Galapagos NV
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hutchison MediPharma Limited
  • Immune Pharmaceuticals, Inc.
  • InDex Pharmaceuticals Holding AB
  • Janssen Biotech, Inc.
  • Kaken Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lipid Therapeutics GmbH
  • Meda AB
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mochida Pharmaceutical Co., Ltd.
  • Morphotek, Inc.
  • Nestle SA
  • Pfizer, Inc.
  • Procter & Gamble Company, The
  • Qu Biologics Inc.
  • Salix Pharmaceuticals, Inc.
  • Shield Therapeutics PLC
  • Shire Pharmaceuticals, Inc.
  • Sterna Biologicals GmbH & Co. KG
  • Takeda Pharmaceuticals Company Ltd.
  • Tillotts Pharma AG
  • TopiVert Ltd.
  • UCB SA
  • Zeria Pharmaceutical Co., Ltd.

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Ulcerative Colitis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 3: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 5: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 6: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 7: World Ulcerative Colitis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 8: World Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Mild UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Mild UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Mild UC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Moderate UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Moderate UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Moderate UC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Severe UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 24: World Historic Review for Severe UC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: World 16-Year Perspective for Severe UC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: USA Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: USA 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 29: USA Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: USA Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: USA 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: USA Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: USA 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Canada 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Canada 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: Canada Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: Canada 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
JAPAN
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 44: Japan Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Japan 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 47: Japan Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Japan Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Japan 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 50: Japan Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Japan Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Japan 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
CHINA
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 53: China Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: China Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: China 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 56: China Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: China Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: China 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 59: China Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: China Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: China 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
EUROPE
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 62: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 65: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 68: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 69: Europe Historic Review for Ulcerative Colitis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 71: Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: Europe Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
FRANCE
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 74: France Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: France Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: France 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 77: France Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: France Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: France 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 80: France Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: France Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: France 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
GERMANY
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 83: Germany Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: Germany Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: Germany 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 86: Germany Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Germany Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: Germany 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 89: Germany Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Germany Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Germany 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
ITALY
  • Table 92: Italy Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Italy Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Italy 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 95: Italy Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 96: Italy Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 97: Italy 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 98: Italy Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 99: Italy Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 100: Italy 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 101: UK Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 102: UK Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 103: UK 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 104: UK Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 105: UK Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 106: UK 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 107: UK Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 108: UK Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 109: UK 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 110: Rest of Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 111: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 112: Rest of Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 113: Rest of Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 114: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 115: Rest of Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 116: Rest of Europe Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 117: Rest of Europe Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 118: Rest of Europe 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Ulcerative Colitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 119: Asia-Pacific Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 120: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Disease Type - Mild UC, Moderate UC and Severe UC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 121: Asia-Pacific 16-Year Perspective for Ulcerative Colitis Therapeutics by Disease Type - Percentage Breakdown of Value Sales for Mild UC, Moderate UC and Severe UC for the Years 2014, 2024 & 2030
  • Table 122: Asia-Pacific Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 123: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Route Of Administration - Oral and Injectables Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 124: Asia-Pacific 16-Year Perspective for Ulcerative Colitis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Injectables for the Years 2014, 2024 & 2030
  • Table 125: Asia-Pacific Recent Past, Current & Future Analysis for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 126: Asia-Pacific Historic Review for Ulcerative Colitis Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 127: Asia-Pacific 16-Year Perspective for Ulcerative Colitis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2024 & 2030
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Amgen, Inc.
  • Arena Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Avaxia Biologics, Inc.
  • BioLineRx Ltd.
  • Celgene Corporation
  • Cosmo Pharmaceuticals NV
  • EA Pharma Co., Ltd.
  • Eisai Co., Ltd.
  • Ferring Pharmaceuticals
  • Galapagos NV
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hutchison MediPharma Limited
  • Immune Pharmaceuticals, Inc.
  • InDex Pharmaceuticals Holding AB
  • Janssen Biotech, Inc.
  • Kaken Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Lipid Therapeutics GmbH
  • Meda AB
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Mochida Pharmaceutical Co., Ltd.
  • Morphotek, Inc.
  • Nestle SA
  • Pfizer, Inc.
  • Procter & Gamble Company, The
  • Qu Biologics Inc.
  • Salix Pharmaceuticals, Inc.
  • Shield Therapeutics PLC
  • Shire Pharmaceuticals, Inc.
  • Sterna Biologicals GmbH & Co. KG
  • Takeda Pharmaceuticals Company Ltd.
  • Tillotts Pharma AG
  • TopiVert Ltd.
  • UCB SA
  • Zeria Pharmaceutical Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJuly 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 7 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.5 Billion
Compound Annual Growth Rate4.4%
Regions CoveredGlobal

Related Topics

Related Reports

Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 146 Pages
  • Global
From
Global Ulcerative Colitis Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Global Ulcerative Colitis Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 190 Pages
  • Global
From
Ulcerative Colitis (UC) - Epidemiology Forecast - 2032 - Product Image

Ulcerative Colitis (UC) - Epidemiology Forecast - 2032

  • Report
  • 147 Pages
  • Global
From
Global Ulcerative Colitis Market - Product Image

Global Ulcerative Colitis Market

  • Report
  • 200 Pages
  • Global
From
Global Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Forecast 2024-2030 - Product Image

Global Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.